Workflow
药品代理合作
icon
Search documents
同源康医药-B高开逾6% 与四川汇宇就TY-9591订立潜在总代理协议
Zhi Tong Cai Jing· 2025-08-27 01:33
Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase in stock price, rising by 6.23% to HKD 16.37, following the announcement of a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huiyu Pharmaceutical's subsidiary, Sichuan Huichenxing [1] Group 1 - The company plans to appoint Sichuan Huichenxing as the exclusive agent for TY-9591 in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this potential agency agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and the agreement is expected to leverage Sichuan Huiyu's extensive sales and agency network [1] Group 2 - Sichuan Huiyu is a mature pharmaceutical enterprise with a complete industrial chain and rich experience in drug agency and sales in China [1] - The arrangement is anticipated to enhance sales and revenue for TY-9591, accelerate market penetration, and reduce the costs associated with establishing new sales channels [1] - Collaborating with a well-known pharmaceutical company is expected to strengthen the company's brand image [1]
同源康医药-B(02410)与四川汇宇就TY-9591订立潜在总代理协议
智通财经网· 2025-08-26 12:39
Core Viewpoint - The announcement indicates that Sichuan Huiyu Pharmaceutical Co., Ltd. has approved a potential agency agreement for the core product TY-9591, which could enhance sales and market penetration in China [1] Group 1: Agreement Details - Sichuan Huichen Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sichuan Huiyu, may be appointed as the exclusive agent for TY-9591 in mainland China, with an initial milestone payment of up to RMB 150 million [1] - The potential agency arrangement is aimed at leveraging the existing sales and distribution network of Sichuan Huichen and Sichuan Huiyu [1] Group 2: Strategic Implications - The arrangement is expected to accelerate market penetration and reduce costs associated with establishing new sales channels for TY-9591 [1] - Collaborating with a well-established pharmaceutical company like Sichuan Huiyu is anticipated to strengthen the company's brand image in the market [1]